

Special Issue

Personalized Treatment and Hereditary Causes of Nephrotic Syndrome

Message from the Guest Editor

Nephrotic Syndrome (NS) is a major cause of chronic and end-stage kidney disease worldwide. Advances in renal genetics over the past three decades have highlighted glomerular visceral epithelial cells (i.e., podocytes) as the principal cell type affected in disease pathogenesis. It is now clear that podocyte injury or loss is a necessary precursor of glomerular dysfunction in NS and studies of familial forms of the disease have identified a variety of molecular targets involved in podocyte actin cytoskeletal dynamics. In this Special Issue, we will highlight: Emerging technologies for characterizing podocyte biology; Novel insights into the mechanisms of podocyte injury; Novel model systems for modeling podocyte injury; Novel methods or approaches for high throughput screening of candidate compounds for podocytopathies; Exploration of podocyte transcriptomics and proteomics in health and disease to identify novel therapeutic targets.

We will be accepting submissions in these areas to assemble a Special Issue focused on the translation of findings in renal genetics into rational therapies for nephrotic syndrome.

Guest Editor

Dr. Gentzon Hall

Department of Internal Medicine, Division of Nephrology, Investigator, Duke Molecular Physiology Institute (DMPi), DUMC, Box 31108, 300 N. Duke Street, Durham, NC 27701, USA

Deadline for manuscript submissions

closed (10 July 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/54279

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://www.mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).